STOCK TITAN

Aptose Biosciences Inc. - $APTO STOCK NEWS

Welcome to our dedicated page for Aptose Biosciences news (Ticker: $APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Biosciences's position in the market.

Rhea-AI Summary
Aptose Biosciences released highlights from a clinical update event featuring its lead compound tuspetinib (TUS). TUS is a precision targeted kinase inhibitor that suppresses select kinases driving the proliferation of acute myeloid leukemia (AML). The combination of TUS with venetoclax (VEN) has shown promising results in difficult-to-treat VEN failure AML patients, with a 44% overall response rate (ORR). TUS directly targets VEN resistance mechanisms, making it a potential treatment option for VEN failure patients. The safety profile of TUS and TUS/VEN combination remains favorable. The company plans to initiate further studies to evaluate the efficacy and duration of response of TUS/VEN in AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.52%
Tags
none
-
Rhea-AI Summary
Aptose Biosciences will report financial results for Q3 2023 on November 9th and provide a corporate update. Analysts can pre-register for the Q&A session and access the audio webcast through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
conferences earnings
-
Rhea-AI Summary
Aptose Biosciences Inc. will provide a clinical update on October 30, 2023, regarding its lead compound tuspetinib, a precision targeted myeloid kinase inhibitor for the treatment of acute myeloid leukemia (AML). The update will include up-to-date clinical data and will be presented by Dr. Naval Daver, the lead investigator on Aptose's APTIVATE trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
Rhea-AI Summary
Aptose Biosciences to participate in Cantor Global Healthcare Conference. Recent clinical data shows positive responses to tuspetinib in AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary
Aptose Biosciences announces $3 million investment from Hanmi Pharmaceutical for its lead hematology drug, tuspetinib, in the APTIVATE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Second tranche of investment up to $4 million pending achievement of milestones. Tuspetinib shows promise in combination with venetoclax.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
-
Rhea-AI Summary
Aptose Biosciences to participate in H.C. Wainwright conference; positive clinical data for tuspetinib in AML patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
Rhea-AI Summary
Aptose Biosciences Inc. (APTO) announces a 50% CRc response rate with Tuspetinib/Venetoclax doublet in evaluable patients, along with CRc percentages in patients who failed prior Venetoclax and in patients with wildtype and mutated FLT3. Hanmi Pharmaceutical commits investment in Aptose up to 19.99% ownership or $7 million. Financial results for the three months ended June 30, 2023, and corporate update revealed. Key corporate highlights include the APTIVATE Phase 1/2 clinical trial of tuspetinib, equity investments in Aptose, and a successful Type B EOP1 meeting with US FDA. Financial results of operations and research and development expenses were also detailed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Aptose Biosciences Inc.

Nasdaq:APTO

APTO Rankings

APTO Stock Data

19.18M
12.52M
19.71%
7.63%
0.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
TORONTO

About APTO

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt